Gastroenteritis
Also known as: Stomach flu
Methodology & AI Transparency ⓘ
Gastroenteritis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is gastroenteritis? Gastroenteritis is an inflammation of the lining of the stomach and intestines.
- 2 Real-world patient consensus: Clinical coding for Gastroenteritis uses ICD-10 K52.9 across IBS, IBD & Colon specialty care.
- 3 Typical cash cost range: Primary evaluation for Gastroenteritis incorporates age/symptom-appropriate colonoscopy or in Gastroenteritis (K52.9: mucosal biopsy) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Gastroenteritis: hs-CRP, CBC & in Gastroenteritis (K52.9: Ferritin) (Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9)) and Fecal Calprotectin [Gastroenteritis K52.9].
Ask our AI Specialists anything about Gastroenteritis
What Is Gastroenteritis?
What is gastroenteritis? Gastroenteritis is an inflammation of the lining of the stomach and intestines. The main symptoms include vomiting and diarrhea . It is usually not serious in healthy people, but it can sometimes lead to dehydration or cause severe symptoms. What causes gastroenteritis? There can be many different causes of gastroenteritis: Viruses Bacteria Parasites Chemicals Reactions to certain medicines and food Viral gastroenteritis is the most common type. It can be caused by many different viruses, including noroviruses and rotaviruses . Some people call viral gastroenteritis the "stomach flu." But this name is not medically correct.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in ibs, ibd & colon, Gastroenteritis (K52.9) involves mucosal tight-junction permeability in Gastroenteritis (K52.9: shifts or immune-mediated). Cross-referenced with NIH MeSH (Gastroenteritis), progression correlates with shifts in hs-CRP, CBC & in Gastroenteritis (K52.9: Ferritin) (Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9)).
Common Symptoms & Clinical Signs
- • Reactions to certain medicines and food
- • Pain or cramping in your abdomen (belly)
- • Presentation of Gastroenteritis (K52.9): rectal bleeding, nocturnal in Gastroenteritis (K52.9: bowel movements, or)
- • Secondary Gastroenteritis clinical sign: recurrent lower abdominal in Gastroenteritis (K52.9: cramping associated with)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Gastroenteritis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K52.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP, CBC & in Gastroenteritis (K52.9: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fecal Calprotectin [Gastroenteritis K52.9] | < 50 mcg/g (K52.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in Gastroenteritis (K52.9: (tTG-IgA)) | Negative (celiac rule-out) (K52.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Gastroenteritis
Treatment selection for Gastroenteritis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gastroenteritis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus: What a 8,200-Participant Study Found TV P2-VP8 provided inferior protection against SRVGE compared to ROTARIX. Vaccine • 2026-01-05 • Phase III Randomized Trial | N = 8,200 | 96/100 | PMID 41319434 ↗ |
| New Insights on Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete: What a 1,382-Participant Study Found Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C. Digestive diseases (Basel, Switzerland) • 2025-01-15 • Phase III Randomized Trial | N = 1,382 | 96/100 | PMID 39701047 ↗ |
| New Insights on Benefits and safety of intravenous vedolizumab treatment in Chinese patients with: What a 215-Participant Study Found There were no new safety findings for vedolizumab treatment of Chinese patients with CD. Clinics and research in hepatology and gastroenterology • 2025-06-15 • Phase III Randomized Trial | N = 215 | 88/100 | PMID 40228712 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Non-Rotavirus Enteric Infections on Vaccine Efficacy in a ROTASIIL Rotavirus continued to be the leading cause of severe GE in this age group. The American journal of tropical medicine and hygiene • 2024-06-05 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38626750 ↗ |
Gastroenteritis Patient Community & “People Like Me” Threads
Filter Gastroenteritis community threads and patient logs by age, biological sex, dosage, and treatment duration.